제품 수집
제품 세부정보
Synonyms
CTLA4, CD152
Source
Biotinylated Human CTLA-4, Fc,Avitag (CT4-H82F3) is expressed from human 293 cells (HEK293). It contains AA Ala 37 - Phe 162 (Accession # P16410-1).
Predicted N-terminus: Ala 37
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 41.8 kDa. The protein migrates as 48-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Labeling
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
Protein Ratio
Passed as determined by the HABA assay / binding ELISA.
Purity
>95% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
고객님도 확인한 상품
데이터 표시
SDS-PAGE
Biotinylated Human CTLA-4, Fc,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Bioactivity-ELISA
Immobilized Human B7-2, Fc Tag (Cat. No. CD6-H5257) at 5 μg/mL (100 μL/well) can bind Biotinylated Human CTLA-4, Fc,Avitag (Cat. No. CT4-H82F3) with a linear range of 0.6-10 ng/mL (QC tested).
Protocol
Immobilized Human B7-1, Fc Tag (Cat. No. B71-H5259) at 5 μg/mL (100 μL/well) can bind Biotinylated Human CTLA-4, Fc,Avitag (Cat. No. CT4-H82F3) with a linear range of 0.6-10 ng/mL (Routinely tested).
Protocol
Immobilized Cynomolgus / Rhesus macaque B7-2, His Tag (Cat. No. CD6-C52H5) at 5 μg/mL (100 μL/well) can bind Biotinylated Human CTLA-4, Fc,Avitag (Cat. No. CT4-H82F3) with a linear range of 0.02-0.625 μg/mL (Routinely tested).
Protocol
Immobilized Biotinylated Human CTLA-4, Fc,Avitag (Cat. No. CT4-H82F3) at 1 μg/mL (100 μL/well) on Streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate, can bind Ipilimumab with a linear range of 0.2-2 ng/mL (Routinely tested).
Protocol
Serial dilutions of Ipilimumab neutralizing antibody (1:2 serial dilutions, from 40 μg/mL to 0.019 μg/mL) were added into Human B7-1, Fc Tag (Cat. No. B71-H5259): Biotinylated Human CTLA-4, Fc,Avitag (Cat. No. CT4-H82F3) binding reactions. The assay was performed according to the above described protocol. Background was subtracted from data points before curve fitting.
Protocol
Serial dilutions of Ipilimumab neutralizing antibody (1:2 serial dilutions, from 40 μg/mL to 0.019 μg/mL) were added into Human B7-2, Fc Tag (Cat. No. CD6-H5257): Biotinylated Human CTLA-4, Fc,Avitag (Cat. No. CT4-H82F3) binding reactions. The assay was performed according to the above described protocol. Background was subtracted from data points before curve fitting.
Protocol
Immobilized Cadonilimab at 1 μg/mL (100 μL/well) can bind Biotinylated Human CTLA-4, Fc,Avitag (Cat. No. CT4-H82F3) with a linear range of 0.2-4 ng/mL (Routinely tested).
Protocol
Immobilized Human PD-1, His Tag (Cat. No. PD1-H5221) at 5 μg/mL, add increasing concentrations of Cadonilimab (PD-1 x CTLA-4 bispecific antibody) and then add Biotinylated Human CTLA-4, Fc,Avitag (Cat. No. CT4-H82F3) at 0.2 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) with sensitivity of 2.99 ng/mL (Routinely tested).
Protocol
사용자 리뷰 댓글 남기기
배경 소개
프론티어 진행
의약품 개발 진행- 영어 이름：
Cytotoxic T-Lymphocyte-Associated Antigen 4
- 카테고리：
- 상장 의약품 수：
5 상세
- 임상 의약품 수：
65 상세
- 최고 개발 단계：
Approved
연락하기
전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521
신약 후보물질 라이선싱
